USPTO serial 79274546
Reviewed by CopyMark Law Group
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Plus Government fees of $325
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Charles G. Zug
Charles G. Zug Nelson Mullins Riley & Scarborough LLP301 S. College St.Suite 2300, IP DepartmentCharlotte, NC 28202| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations and substances for the treatment and/or diagnosis of cancer and infectious diseases; biotechnologically-formed enzyme preparations for medical purposes; medicinal preparations for the treatment of cancer and infectious diseases; monoclonal antibodies for therapeutic purposes; products containing antibodies for use in medicine, namely, diagnostic kits consisting primarily of monoclonal antibodies used in the capture of specific biological markers for use in disease testing; proteins for binding antibodies for medical use; proteins for detecting antibodies for medical use; reagents for medical use, namely, for use in the development of monoclonal antibodies; diagnostic biomarker reagents for medical purposes; tagged antibodies for medical use; vaccines; vaccines against cancer, viral, and bacterial infection; vaccines for human use; diagnostic preparations and reagents for medical purposes; vaccine adjuvants; diagnostic preparations, reagents, and substances for medical purposes; diagnostic products and testing materials for medical purposes, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in capturing and purifying specific biological markers for use in disease testing; reagents for use in diagnostic tests for medical purposes; medical diagnostic reagents for capturing and purifying specific biological markers that can be utilised in therapeutics or diagnostics; cells for growing recombinant human protein for medical purposes; recombinant DNA technology proteins for medical use; biological reagents for use in molecular biology, namely, reagents for medical use for capturing and purifying specific biological markers that contain nucleic acid; antibodies that are specifically able to bind and capture specific biological markers for medical purposes; antibody fragments that are specifically able to bind and capture specific biological markers for medical purposes; antibody conjugates that are specifically able to bind and capture specific biological markers for medical purposes; pharmaceutical preparations for the treatment, reconstruction and repair of antibodies; immunological antibodies for medical use; monoclonal antibodies for medical diagnostic use; monoclonal antibodies for medical use | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Jan 19, 2026 | REM3 | COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED | — |
| May 16, 2021 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Apr 23, 2021 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Apr 23, 2021 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Apr 19, 2021 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Jan 29, 2021 | ADCH | CHANGE OF NAME/ADDRESS REC'D FROM IB | — |
| Jan 19, 2021 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Nov 3, 2020 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Nov 3, 2020 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Nov 2, 2020 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Oct 14, 2020 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Oct 14, 2020 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Oct 14, 2020 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 24, 2020 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 10, 2020 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Sep 9, 2020 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Sep 9, 2020 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 27, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 9, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 9, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Feb 19, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Feb 18, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Feb 12, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Dec 27, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 23, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 19, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |